Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up

Biogen reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected.

Comments are closed.